Introduction
============

Breast cancer ranks as the second most prevalent cancer[@b1-ott-8-2967] and one of the most common malignancies affecting women around the world with a mortality rate of more than one million per year.[@b2-ott-8-2967] Numerous physiological agents and pathological conditions as well as environmental risk factors have been proposed to influence the development of this neoplasia. Among these, thyroid hormone (triiodothyronine, T3, and its precursor thyroxine, T4) has long been postulated since Beatson described the use of thyroid extracts for metastatic breast cancer treatment more than a century ago.[@b3-ott-8-2967]

Thyroid hormones control the development and maintenance of homeostasis of various organs in vertebrates. These cellular effects are mediated by the binding of T3 to thyroid hormone receptors (TRs), which are located within the nuclei of target cells.[@b4-ott-8-2967] TRs are encoded by two genes, TRα and TRβ, which are located on human chromosomes 17 and 3, respectively. By alternative splicing and differential promoter usage, these two genes have been determined to encode for nine polypeptides, of which four bind T3 and are functional receptors, namely, TRα1, TRβ1, TRβ2, and TRβ3.[@b5-ott-8-2967] Several recent studies have strongly suggested that TRβ1 might be involved in the pathogenesis of human cancers.[@b6-ott-8-2967]--[@b8-ott-8-2967] Nonetheless, studies on TRβ1 in human breast cancer are limited, and only a few have described the abnormal expression of TRβ1 in breast tumors and breast cancer cell lines.[@b9-ott-8-2967],[@b10-ott-8-2967] Our earlier study has shown that hypermethylation of the *TRβ1* promoter frequently occurred in breast tumors, and an inverse relationship exists between *TRβ1* promoter methylation and *TRβ1* mRNA expression.[@b11-ott-8-2967] However, promoter methylation could not explain all cases that lost expression of *TRβ1* mRNA and it only partially contributed to the loss of *TRβ1* expression.

Inactivation of the TRβ1 gene in breast cancer might be related to other mechanisms. Several reports have indicated a close association between somatic mutations of *TRβ1* and human cancers.[@b12-ott-8-2967]--[@b14-ott-8-2967] On the basis of these observations, we wanted to determine the involvement of *TRβ1* mutations in the pathogenesis of breast cancer in the Chinese population and its contributory role in the loss of *TRβ1* expression. Therefore, we screened for *TRβ1* mutations within exons 7--10, which have been reported to be hotspots for renal cancer,[@b15-ott-8-2967] as well as analyzed its relationship with the mRNA expression of *TRβ1*.

Materials and methods
=====================

Biological specimens
--------------------

Tumor and corresponding nontumor tissues not infiltrated by tumors and confirmed by a pathologist were collected from 105 breast cancer patients who underwent breast resection at the Gansu Province People Hospital, Lanzhou General Hospital and Lanzhou University First Hospital from 2006 to 2013. The patients were excluded with thyroid diseases or abnormal thyroid status testing. The patients were female within the age range of 32--65 years (median, 48 years). Breast cancers were classified according to the tumor-node-metastasis scheme and differentiation stage. The surgical specimens obtained from these patients were immediately frozen in liquid nitrogen and stored at −70°C for analysis. All samples were obtained with informed consent, and the ethical committees of the Gansu Province People Hospital, Lanzhou General Hospital, and Lanzhou University First Hospital authorized the study.

Real-time quantitative RT-PCR analysis of *TRβ1* expression
-----------------------------------------------------------

Total RNA from tissues was extracted using Trizol solution. Reverse transcription (RT) was performed in a 20 μL reaction system according to the manufacturer's recommendation. To analyze *TRβ1* mRNA expression, real-time quantitative RT-polymerase chain reaction (RT-PCR) was performed. Briefly, RT-PCR amplification was carried out for each sample in a 12.5 μL final reaction mixture containing 1 μL of cDNA, 3 nM TaqMan probe, 5.5 mM MgCl~2~, 10 nM of each primer, 0.6 U of Platinum Taq polymerase, and 200 μM of deoxyguanosine triphosphate. After an initial denaturation step at 95°C for 1.5 minutes, 40 cycles of 15 seconds at 95°C and 56 seconds at 60°C for annealing and extension were run on an iQ5 PCR machine (Bio-Rad Laboratories, Hercules, CA, USA).

*TRβ1* mRNA levels were normalized to β-actin. The primer sequences used in the present study are presented in [Table 1](#t1-ott-8-2967){ref-type="table"}. All reactions were performed in duplicate. The relative expression of *TRβ1* was analyzed by the comparative Ct method. Thermal dissociation plots were examined for biphasic melting curves.

PCR-single-strand conformation polymorphism (SSCP) analysis
-----------------------------------------------------------

DNA was extracted from tumor and corresponding nontumor tissue samples using standard methods. The primers used in this analysis are summarized in [Table 1](#t1-ott-8-2967){ref-type="table"}. PCR was performed for 35 cycles with the appropriate annealing temperatures. The bands were excised from agarose gels and purified with GFX Amersham Kit (Qiagen, Valencia, CA, USA), following the manufacturer's protocol. After PCR analysis, the reaction mixture was mixed with an equal amount of 95% formamide containing bromophenol blue and 20 mM EDTA, then incubated at 94°C for 7 minutes and electrophoresed on a Gene-Phor system (Bio-Rad Laboratories) at 15°C. The gels were stained using a silver staining method, and bands were visualized and photographed. Samples that showed band-shifts different from the wild-type bands were identified as mutants and submitted for sequencing.

Automated sequencing
--------------------

The samples that showed variant band-shifts in single-strand conformation polymorphism (SSCP) were reamplified for sequencing. DNA sequencing was performed using an automated sequencer ABI PRISM 310 (Thermo Fisher Scientific, Waltham, MA, USA). The process of sequencing was conducted twice to stringently confirm and classify the mutations.

Statistical analysis
--------------------

Statistical analysis was performed using the SPSS 10.0 software (SPSS Inc., Chicago, IL, USA). The data are expressed as the mean ± SD. The values of mRNA expression level were analyzed by independent samples *t*-test or paired-samples *t*-test. The chi-square test was utilized to analyze the relationship between *TRβ1* mutations and pathology parameters. *P*-values less than 0.05 were designated as statistically significant.

Results
=======

*TRβ1* mRNA expression is frequently downregulated in Chinese breast cancer patients
------------------------------------------------------------------------------------

We analyzed the mRNA expression of *TRβ1* in 105 pairs of breast cancer specimens and matched normal tissues by real-time quantitative RT-PCR. The mRNA expression level of *TRβ1* was reduced in 84 of the 105 (80%) breast cancer tissue samples compared with the matched normal tissues. The mean mRNA expression level of the breast cancer tissue samples was 3.08±4.06, compared with 12.84±11.6 in matched normal tissues. Statistical analysis showed that *TRβ1* mRNA expression was significantly reduced in breast cancer tissues (*P*=0.02).

Mutational analysis of the *TRβ1* gene of Chinese breast cancer patients
------------------------------------------------------------------------

Changes or shifts in electrophoretic mobility of single-strand DNA bands of exons 7--10 of the *TRβ1* were analyzed relative to that of the wild-type, which has been deposited in Genebank and its GeneID is 7068. Samples that showed alterations were identified as SSCP-positive and were then sequenced to confirm and classify the detected mutation. The mutations found were exclusively associated with the breast tumor samples and were not present in the normal adjacent tissue samples. A total of 20 samples (19.04%) showed truncating mutations in the exons 7--10 of the *TRβ1* gene, as listed in [Table 2](#t2-ott-8-2967){ref-type="table"}. Among these, eight cases harbored frame shift mutations (five cases of c.850insA in exon 7 and three cases of c.1028delA in exon 8), and the remaining were missense mutations that were observed in 12 cases of breast cancer ([Figure 1](#f1-ott-8-2967){ref-type="fig"}; [Table 2](#t2-ott-8-2967){ref-type="table"}). Interestingly, mutations were identified in exons 7--9. However, no mutation was identified in exon 10.

To evaluate the possible pathogenicity of the observed changes, we analyzed the relationship between *TRβ1* gene mutation and the clinicopathological characteristics of the tumor specimens ([Table 3](#t3-ott-8-2967){ref-type="table"}). Highly significant associations between the mutation profile of *TRβ1* and menopausal stage and estrogen receptor (ER) status were observed. On the other hand, no association between the mutation profile of the *TRβ1* gene and other clinicopathological characteristics such as tumor stage were detected (*P*\>0.05).

Relationship between *TRβ1* mutations and *TRβ1* mRNA expression profiles in Chinese breast cancer patients
-----------------------------------------------------------------------------------------------------------

A strong correlation between mutations and mRNA expression levels of *TRβ1* of the 20 Chinese breast cancer patients was observed. The mean mRNA expression level of the 20 breast cancer tissues samples that harbored mutations was 2.98±4.12, compared with 13.44±10.6 in the matched normal tissues. The difference of gene mutation and mRNA expression was statistically significant (*P*\<0.05).

Discussion
==========

There is an increasing research evidence that the aberrant expression and mutation of the TRβ1 gene could be associated with the development of human neoplasms.[@b12-ott-8-2967],[@b13-ott-8-2967],[@b16-ott-8-2967]--[@b19-ott-8-2967] Transgenic mice (TRβ^PV/PV^) harboring a PV mutation that was originally identified in a patient with thyroid hormone resistance spontaneously developed thyroid cancer.[@b20-ott-8-2967] However, information on whether *TRβ1* mutations are associated with breast cancer is limited. Only two reports described a totally different situation regarding *TRβ1* gene mutations. Silva et al reported the presence of truncated *TRβ1* mRNA in 6 of 70 sporadic breast cancer patients (9%),[@b21-ott-8-2967] and Li et al described the absence of mutations in the *TRβ1* gene in sporadic breast cancers.[@b22-ott-8-2967] The present study aimed to clarify this controversy and to establish whether *TRβ1* gene mutations contribute to breast carcinoma development/progression in the Chinese population.

The present study screened for mutations in the *TRβ1* gene that spans exons 7--10 that were previously reported as hotspots in renal cancer.[@b15-ott-8-2967] *TRβ1* gene mutations were identified in 20 out of 105 patients. Five cases harbored frame shift mutations in exon 7, three cases showed frame shift mutations in exon 8, and the remaining were missense mutations. In one study, point mutations in *TRβ1* cDNA that were detected using the mismatch RNase cleavage assay were observed in 76% (13/17 tumors) of human hepatocellular carcinomas.[@b12-ott-8-2967] Puzianowska-Kuznick et al[@b13-ott-8-2967] reported that mutations in the *TRβ1* cDNA were detected in 93.75% of papillary thyroid carcinomas. Kamiya et al[@b15-ott-8-2967] demonstrated that approximately 30% (7 of 22) of *TRβ1* cDNA was mutated in human renal clear cell carcinomas and that most of the mutations were localized within the hormone-binding domain. Comparison of the mutation sites showed that the mutations detected in the present study were novel. However, the loss-of-function mutation in the *TRβ1* gene detected in the present study was similar to that described in a previous study, wherein a loss of the hormone-binding and transcriptional activity and the development of dominant-negative activity were observed. In addition, the loss-of-function mutation in the TRβ1 gene might also affect the protein--protein interactions in the network of cellular proto-oncogenes and tumor suppressors. For example, TRβ1 was shown to physically associate with the tumor suppressor protein p53.[@b23-ott-8-2967],[@b24-ott-8-2967] TRs also stimulate the expression of the c-fos and c-jun proto-oncogenes, increase expression of the c-Fos and c-Jun proteins, and activate AP1 transcriptional activity via a T3-independent pathway.[@b25-ott-8-2967]--[@b27-ott-8-2967]

We also analyzed the relationship between *TRβ1* mutations and clinical pathological features. Li et al[@b22-ott-8-2967] reported that although no significant correlation between alterations in TRβ1 expression and any clinical feature was observed, an association between alterations in expression and early onset cancer (patients with ages \<50 years) was detected. In the present study, a significant association between *TRβ1* mutations and menopausal and ER status was observed. The majority of the mutations in the *TRβ1* gene were detected in premenopausal patients (15/20, 32.61%). We also found a significant association between *TRβ1* mutations and ER status, where the majority of mutations (16/20, 25.39%) were observed in ER-negative patients. These findings suggest that breast cancer patients harboring *TRβ1* mutations are likely to follow a more aggressive course and generate a worse prognosis.

Our earlier study discovered that *TRβ1* promoter hypermethylation frequently occurred in breast tumor tissues, and that there was an inverse relationship between *TRβ1* promoter methylation and mRNA expression.[@b11-ott-8-2967] However, promoter methylation could not explain all cases that lost the expression of *TRβ1* mRNA, thus indicating that this post-translational activity only partially contributed to the loss of *TRβ1* expression. The present study demonstrated that mutation in the *TRβ1* gene also contributed to mRNA expression. The 20 cases with mutation in the *TRβ1* gene showed reduced expression of *TRβ1* mRNA compared with that in matched normal tissues. Interestingly, three cases without *TRβ1* promoter methylation but showing reduced expression in our previous study were determined to harbor a specific mutation in which an A nucleotide was deleted in exon 8. This observation suggests that *TRβ1* mutations in breast cancer partially contributed to the loss of *TRβ1* expression. Compared with our previous study, we also discovered that 13 cancer cases harbored both mutation and promoter hypermethylation that might have led to the complete inactivation of *TRβ1*. According to Knudson's proposed two-hit hypothesis, disruption of both copies of a given gene is required for the complete loss of function of a tumor suppressor gene.[@b28-ott-8-2967] Our findings correlate with Knudson's model. Abnormal methylation of the promoters of tumor suppressor genes has been established as the second hit, with intragenic mutations being the first hit.[@b29-ott-8-2967]

Conclusion
==========

To our knowledge, this is the first investigation involving mutation screening of the *TRβ1* gene that resulted in a decrease in *TRβ1* mRNA expression in Chinese breast cancer cases. This finding suggests that mutations in the *TRβ1* gene might be the underlying mechanism for *TRβ1* partial inactivation and thus may be used as a prognostic biomarker. However, our study was conducted on a limited number of cases. Therefore, further large-scale progressive studies on different exons and introns are required to establish the definitive role of TRβ1 in the pathogenesis of breast cancer.
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![Sequencing chromatograms show two mutations in *TRβ1* gene (c.850insA in exon 7 and c.1028delA in exon 8, marked by arrows) and corresponding wild-type sequences.\
**Notes:** (**A**) Mutant type of exon 7, (**B**) mutant type of exon 8, (**C**) wild type of exon 7, (**D**) wild type of exon 8.\
**Abbreviations:** mut, mutant type; *TRβ1*, thyroid hormone receptor β1; wt, wild type.](ott-8-2967Fig1){#f1-ott-8-2967}

###### 

Primer and probe sequences used in this study

                      Forward primer sequence (5′→3′)   Probe sequence (5′→3′)[\*](#tfn1-ott-8-2967){ref-type="table-fn"}   Reverse primer sequence (5′→3′)
  ------------------- --------------------------------- ------------------------------------------------------------------- ---------------------------------
  Real-time RT-PCR                                                                                                          
   *TRβ1*             CCAGAAGACATTGGACAAGCA             FAM-ATCATCACACCAGCAATTACCAGAGTGGTGT-AMRA                            GCAGCTCACAAAACATAGGCA
   β-actin            GCTCGTCGTCGACAACGGCTC             FAM-TGGCGGCACCACCATGTACC-AMRA                                       CAAACATGATCTGGGTCATCTTCTC
  PCR-SSCP (*TRβ1*)                                                                                                         
   Exon 7             GCATCTGTGTGCCTTGTCTC                                                                                  TGAGGTAGAAAACACTGGCATA
   Exon 8             CAACTTCTTCATTTAAATCTTTCTTTT                                                                           ATTCCTGGAAACTGATGAAACTAT
   Exon 9             TGTTGTTCCTGACTGGCATT                                                                                  AGCGCTAGACAAGCAAAAGC
   Exon 10            TAAAGGCCTGGAATTGGACA                                                                                  GGCAATGGAATGAAATGACA

**Note:**

There is no probe sequence in SSCP for exons 7--10.

**Abbreviations:** PCR-SSCP, polymerase chain reaction-single strand conformation polymorphism; RT-PCR, reverse transcription polymerase chain reaction; SSCP, single strand conformation polymorphism; *TRβ1*, thyroid hormone receptor β1.

###### 

*TRβ1* gene mutation(s) in breast cancer

  Exon   Nucleotide change   Effect on protein   Mutation effect     Number of cases
  ------ ------------------- ------------------- ------------------- -----------------
  7      c.850insA           NA                  Frame shift         5
  8      c.1024C\>G          Pro247Ala           Missense mutation   4
  8      c.1028delA          NA                  Frame shift         3
  9      c.1188G\>A          Glu324Lys           Missense mutation   3
  9      c.1336G\>C          Lys351Asp           Missense mutation   5

**Abbreviations:** NA, not applicable; *TRβ1*, thyroid hormone receptor β1.

###### 

Correlation between mutation of *TRβ1* and clinicopathological features of breast cancer patients

  Clinicopathological features   Patients (n)   Mutation, n (%)   *χ*^2^   *P*-value
  ------------------------------ -------------- ----------------- -------- -----------
  Age (years)                                                              
   \>50                          49             7 (14.28%)        1.351    0.245
   ≤50                           56             13 (23.21%)                
  Tumor stage                                                              
   Stage II                      45             13 (28.89%)       0.623    0.430
   Stage III, stage IV           60             7 (11.67%)                 
  Menopausal status                                                        
   Pre                           46             15 (32.61%)       9.764    0.002
   Post                          59             5 (8.474%)                 
  ER status                                                                
   Positive                      42             4 (9.52%)         4.118    0.042
   Negative                      63             16 (25.39%)                

**Abbreviations:** ER, estrogen receptor; *TRβ1*, thyroid hormone receptor β1.
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